Plasma enterolactone or intestinal Bifidobacterium levels do not explain adenoma formation in multiple intestinal neoplasia (Min) mice fed with two different types of rye-bran fractions.
The study was designed to evaluate whether two types of rye-bran fractions result in distinct bifidogenic effect or enterolactone production in multiple intestinal neoplasia (Min) mice and whether these parameters are associated with intestinal tumorigenesis in this animal model. The experimental diets were a non-fibre diet (control), a rye-bran diet, and diets containing either the soluble extract or the insoluble fraction prepared from rye bran. The main result on adenoma formation in these experiments was the observation that the soluble extract increased number (P=0.012) and size (P=0.008) of adenomas in the distal small intestine when compared with the non-fibre group. All rye-supplemented diets supported similarly the in vivo growth of Bifidobacterium (10(8)-10(9) colony forming units/g) in Min mice, whereas the non-fibre diet lowered intestinal Bifidobacterium below the level of detection. The results show that water solubility does not affect the bifidogenicity of rye bran. Mean plasma enterolactone concentration was highest in the rye-bran group (30.0 nmol/l; P=0.002), which along with the soluble-extract group (16.2 nmol/l; P=0.024) differed significantly from the non-fibre diet group (7.5 nmol/l). Thus, the mice fed with the rye bran were the best enterolactone producers. In conclusion, rye bran and rye fractions influence adenoma formation in Min mice to a varying degree but plasma enterolactone levels or the production of bifidogenic bacteria do not mediate the effect.
Oikarinen
S
S
Department of Applied Chemistry and Microbiology, Division of Nutrition, PO Box 27, FIN-00014 University of Helsinki, Finland. Seija.Oikarinen@Helsinki.fi
Heinonen
S
S
Karppinen
S
S
Mättö
J
J
Adlercreutz
H
H
Poutanen
K
K
Mutanen
M
M
D015107:4-Butyrolactone / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism*; D000818:Animals; D001644:Bifidobacterium; D004043:Dietary Fiber / Q000008:administration & dosage*; D017491:Genes, APC; D007414:Intestinal Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000382:microbiology; D007420:Intestine, Large / Q000378:metabolism* / Q000382:microbiology; D017705:Lignans / Q000097:blood / Q000378:metabolism*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D023421:Models, Animal; D010936:Plant Extracts / Q000008:administration & dosage; D011897:Random Allocation; D012434:Secale
D004043:Dietary Fiber; D017705:Lignans; D010936:Plant Extracts; D015107:4-Butyrolactone; C029497:2,3-bis(3'-hydroxybenzyl)butyrolactone